Capsulution NanoScience AG acquires patents of
former Aventis Research & Technologies
Berlin (March 27, 2003) - Through the acquisition of a patent family that has been part of intellectual property owned by former Aventis Research & Technologies at the beginning of March, Capsulution NanoScience has secured itself the rights to several novel drug delivery formats.

The patents protect various applications of microparticles that are based on so-called polyelectrolyte complexes. These microparticles are suitable as carriers for pharmaceutical or diagnostic drugs. They enable a more patient-orientated delivery of medicaments into the body particularly with regard to a controlled drug release within a specific time frame. Consequently, such drug-loaded particles could act as components of modern medications that improve the delivery of highly effective drug molecules such as peptides, proteins, nucleic acids or even vaccines. The particular polyelectrolyte complexes are charged macromolecules, many of which display an excellent degree of biocompatibility. Capsulution is already applying polyelectrolytes in the manufacture of its nano- and micron-sized capsules.

Following the acquisition, the Berlin-based company has significantly broadened its intellectual property basis and strengthened its expertise as a developer of novel drug delivery systems. At the same time Capsulution has secured an option to extend its range of products.

About Capsulution NanoScience AG:
Capsulution NanoScience develops innovative drug-delivery systems for the simple, efficient and safe delivery of pharmaceutically active compounds. The company applies the so-called LBL-Technology® to build-up the walls of nano- and micro-capsules in a layer-by-layer fashion. This technology is a high-tech tool for the creation of nano- and micro-sized capsules. Based on their minute size, their functionality and their highly reproducible production process the capsules can be used for a multitude of different applications. Accordingly, the precisely sized capsules (100 nm to 100 µm) can be made to function in a manner to suit the intended application, and can be given the appropriate biochemical, electrical, optical and magnetic properties as required by the customer. The capsules are already applied for the delivery of drugs, in cosmetic products, in diagnostics, and for crop protection. Today, the Berlin-based company has 20 employees. In 2001 Capsulution successfully completed its first round of financing raising around three million Euro. Investors in the company include venture capital companies like Berlin Capital Fund (BCF), BC Brandenburg Capitalö, and tbg, the Technologiebeteiligungsgesellschaft (Technology Equity Company) of the Deutsche Ausgleichsbank. Capsulution has already entered into several co-operation agreements with industrial corporations, such as with Bayer AG, Gelita and other renowned companies.

Contact:
Capsulution NanoScience AG
Alexander Herrmann (CFO)
Volmerstr. 7b
D- 12489 Berlin, Germany
Tel.: +49-(0)30-63923627
Fax.: +49-(0)30-63923601
eMail: alexander.herrmann@capsulution.com 
Web: www.capsulution.com 

© BIOCOMMUNICATIONS.net GmbH, Brunnenstr. 128, D-13355 Berlin, Germany - Reprint free of charge, please supply copy